Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to treat patients with genetically defined diseases that have high unmet medical needs. Its lead product candidate is pociredir, a fetal hemoglobin inducer currently in a Phase 1b clinical trial for sickle cell disease and beta-thalassemia. The company also has discovery programs targeting diamond-blackfan anemia, bone marrow failure syndromes, novel fetal hemoglobin inducers, and fibrotic disorders. Fulcrum Therapeutics operates in the United States and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol FULC. The company trades in U.S. dollars (USD), which is the currency of its primary listing exchange. As a U.S.-based company, its shares are available for trading on this major American stock exchange, providing liquidity and visibility to investors interested in the biotechnology sector.

Fulcrum Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing small molecule therapies for genetically defined diseases. The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory oversight. Fulcrum's work in areas like sickle cell disease and beta-thalassemia places it at the forefront of innovative treatments for rare genetic disorders.

Fulcrum Therapeutics is headquartered in Cambridge, Massachusetts, United States. The company primarily serves the U.S. market, as indicated by its focus on the region and its listing on a U.S. exchange. Its clinical trials and research activities are conducted within the United States, targeting patients with genetically defined diseases. While the company may eventually expand globally, its current operations and regulatory filings are centered on the U.S. healthcare system.

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company that does not yet have approved products on the market, so it currently generates no revenue from product sales. Its business model involves advancing its pipeline of small molecule candidates through preclinical and clinical development, with the goal of obtaining regulatory approval and eventually commercializing therapies. The company has a license agreement with CAMP4, which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. This partnership may provide future milestone payments or royalties if products are successfully developed. Until then, Fulcrum relies on equity financing, grants, and collaborations to fund its operations.